Navigation Links
Cepheid Schedules 2010 Third Quarter Financial Results Announcement and Webcast
Date:10/7/2010

SUNNYVALE, Calif., Oct. 7 /PRNewswire-FirstCall/ -- Cepheid today announced that it will report financial results for its third quarter ended September 30, 2010, on Thursday, October 21, 2010, after the close of the market.

The company will host a management presentation at 2 p.m. Pacific Time on Thursday, October 21, 2010, to discuss the results.  To access the live webcast, please visit Cepheid's website at www.cepheid.com/investors at least 15 minutes before the scheduled start time to download any necessary audio or plug-in software.  A replay of the webcast will be available shortly following the call and will remain available for at least 90 days.

Interested participants and investors may also listen to the live teleconference call by dialing (866) 788-0538 (domestic) or (857) 350 1676 (international), and entering participant code 51795047.  A replay will be available for seven days beginning at 4 p.m. Pacific Time.  Access numbers for this replay are (888) 286-8010 (domestic) and (617) 801-6888 (international), with passcode 72854495.

About CepheidBased in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is an on-demand molecular diagnostics company that develops, manufactures, and markets fully-integrated systems and tests for genetic analysis in the clinical, industrial and biothreat markets.  The company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures.  The company's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges.  Through its strong molecular biology capabilities, the company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market.  See http://www.cepheid.com for more information.CONTACTS:For Media Inquiries:For Investor Inquiries:Jared TiptonJacquie RossCepheid Corporate CommunicationsCepheid Investor RelationsTel: (408) 400 8377Tel: (408) 400 8329jared.tipton@cepheid.cominvestor.relations@cepheid.com
'/>"/>

SOURCE Cepheid
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cepheid to Webcast Upcoming Financial Presentations
2. Cepheid Expands Leadership Team With Appointment of Executive Vice President of Worldwide Commercial Operations
3. Cepheid Schedules 2009 Third Quarter Financial Results Announcement and Webcast
4. Cepheid Schedules 2009 Second Quarter Financial Results Announcement and Webcast
5. Cepheid Announces Symposium Speakers and Program Highlights for 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
6. Cepheid Reports 2009 First Quarter Results
7. Cepheid Schedules Fiscal 2009 First Quarter Financial Results Announcement and Webcast
8. Cepheid Announces New Diagnostic Technology to Aid World Efforts in Halting the Spread of Mycobacterium Tuberculosis (TB)
9. Cepheid Announces Preliminary 2008 Fourth Quarter and Full Year Revenue Results
10. Cepheid to Webcast Upcoming Financial Presentations
11. Cepheid Accelerates Direct Sales Channel in UK With Pending Acquisition of Medical Distributor Stretton Scientific
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Renova™ Therapeutics, a ... heart failure and type 2 diabetes, announced that ... novel adeno-associated virus (AAV) vector developed in the ... Ph.D., at Stanford University. The company plans to ... gene therapy product pipeline. "Early ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... SDK that provide essential device-to-computer interconnect using USB or PCI Express, announced the ... support. The FOMD-ACV-A4 is a small, thin, SODIMM-style module that fits a standard ...
(Date:12/8/2016)... 2016  Anaconda BioMed S.L., a pre-clinical stage medical ... generation neuro-thrombectomy system for the treatment of Acute Ischemic ... MD to join its Scientific Advisory Board (SAB). The ... of scientific and clinical experts to Anaconda BioMed S.L., ... BRAIN ® to its clinical phase. The SAB ...
(Date:12/8/2016)... ... December 08, 2016 , ... Microbial genomics leader, ... uBiome is one of just six company finalists in the Health & Medicine ... uBiome, companies nominated as finalists in this year’s awards include Google, SpaceX, Oculus, ...
Breaking Biology Technology:
(Date:12/7/2016)... -- According to a new market research report "Emotion Detection and ... Recognition), Service, Application Area, End User, And Region - Global Forecast to 2021", ... Billion in 2016 to USD 36.07 Billion by 2021, at a Compound Annual ... ... MarketsandMarkets Logo ...
(Date:12/7/2016)... 7, 2016   Avanade is helping Williams ... teams in history, exploit biometric data in order to ... maintain the competitive edge against their rivals after their ... Avanade has worked with Williams during the 2016 ... data (heart rate, breathing rate, temperature and peak acceleration) ...
(Date:12/6/2016)... , Dec. 6, 2016  Zimmer Biomet Holdings, Inc. (NYSE ... priced an offering of €500.0 million principal amount of its ... amount of its 2.425% senior unsecured notes due 2026. ... occur on December 13, 2016, subject to the satisfaction of customary ... basis. The Company intends to ...
Breaking Biology News(10 mins):